DrugTheGuide
Pharmacokinetics · Antimicrobials

Time Above MIC %T>MIC

The percentage of the dosing interval during which free drug concentration exceeds the MIC of the target pathogen. The primary pharmacodynamic driver of efficacy for beta-lactams and other time-dependent antibiotics — more time above MIC, not higher peak levels, predicts bactericidal activity.

Definition and Clinical Significance

Antibiotic pharmacodynamics can be classified into three killing patterns — each with a different PK/PD index as the primary efficacy driver:

Killing pattern PK/PD index Drug classes Dosing implication
Time-dependent %T>MIC Beta-lactams (penicillins, cephalosporins, carbapenems), clindamycin Frequent dosing or extended infusion; dose size less critical
Concentration-dependent Cmax/MIC Aminoglycosides, metronidazole High pulse dose; once-daily dosing maximises peak/MIC
Concentration + time AUC/MIC (AUIC) Fluoroquinolones, vancomycin, azithromycin Balance peak and duration; total daily dose drives AUIC

Reference: Craig, Clin Infect Dis 1998 — PK/PD principles of antibiotic dosing (PubMed) ↗; NCBI StatPearls pharmacokinetics ↗.

Beta-Lactam Dosing Strategies for Maximising T>MIC

Standard intermittent IV bolus dosing (e.g. piperacillin-tazobactam 4.5 g q8h over 30 minutes) achieves high peak concentrations that fall rapidly, resulting in low %T>MIC for pathogens with elevated MICs (e.g. ESBL-producing Enterobacterales, Pseudomonas aeruginosa). Three strategies improve %T>MIC:

  • Increased dosing frequency — q4h vs q6h vs q8h. More frequent smaller doses maintain concentrations above MIC for a larger proportion of the interval.
  • Extended infusion — piperacillin-tazobactam 4.5 g over 4 h (vs 30 min). Achieves near-100% T>MIC for organisms with MIC ≤ 16 mg/L in multiple ICU studies. Stability limits: pip-tazo 4 h; meropenem 3–4 h at room temperature. See Lodise et al. 2007 extended infusion pip-tazo (PubMed) ↗.
  • Continuous infusion — 24-hour infusion after loading dose; used in critically ill patients with Pseudomonas or Acinetobacter where target attainment with intermittent dosing is inadequate. Drug stability must be verified.

Current antibiotic shortage context: see our ceftazidime-avibactam and aztreonam-avibactam shortage news and drug shortage guide. For antimicrobial stewardship frameworks governing these decisions see antimicrobial stewardship guide.

Recommended %T>MIC Targets

Drug Bacteriostasis target Bactericidal target Severe infection target
Penicillins (ampicillin, pip-tazo) 30% 40–50% 50–60%
Cephalosporins (ceftriaxone, cefepime) 30% 40–50% 60–70%
Carbapenems (meropenem, imipenem) 20–30% 40% 50–100%
Aztreonam 30% 40% 60%

FAQ

What is %T>MIC and which antibiotics use it?
T>MIC (time above MIC) is the percentage of the dosing interval during which the free (unbound) drug concentration exceeds the MIC of the target pathogen. It is the primary PK/PD index predicting the efficacy of time-dependent antibiotics, where bactericidal activity correlates with duration of exposure rather than peak concentration. The major drug classes with time-dependent killing and %T>MIC as the primary index are: beta-lactams (penicillins, cephalosporins, carbapenems, monobactams), carbapenems, and macrolides (azithromycin has a time/AUC mixed mechanism).
What %T>MIC target is needed for bactericidal effect?
For most beta-lactams, bacteriostasis requires %T>MIC ≥ 30–40% and bactericidal activity (99.9% killing) typically requires %T>MIC ≥ 40–50% for penicillins and cephalosporins, and ≥ 40% for carbapenems. For immunocompromised patients, higher targets (≥ 60–70%) are often recommended. For carbapenems targeting resistant Pseudomonas or Acinetobacter, extended or continuous infusion strategies targeting 100% T>MIC are used in clinical practice. Exact targets vary by drug, organism, and clinical context.
How does extended and continuous infusion of beta-lactams improve T>MIC?
Standard intermittent bolus dosing achieves T>MIC for a limited portion of the dosing interval. Extended infusion (3–4 hour infusion of piperacillin-tazobactam, meropenem) or continuous infusion achieves near-100% T>MIC for organisms with higher MICs, improving outcomes in severe infections caused by resistant pathogens. Extended infusion is now standard in many ICU protocols for piperacillin-tazobactam and meropenem. Stability of the antibiotic in solution limits continuous infusion feasibility for some beta-lactams.
How does %T>MIC differ from Cmax/MIC and AUC/MIC?
Three PK/PD indices predict antibiotic efficacy: (1) %T>MIC (time-dependent killing) — for beta-lactams, carbapenems, clindamycin; (2) Cmax/MIC (concentration-dependent killing, peak-dependent) — for aminoglycosides, fluoroquinolones; here high peak concentration relative to MIC drives efficacy, supporting once-daily aminoglycoside dosing; (3) AUC/MIC (AUC-dependent, concentration × time) — for fluoroquinolones (AUIC = 24-hour AUC/MIC; target ≥ 125 for gram-negative respiratory infections) and vancomycin (AUC/MIC ≥ 400–600 in current guidelines). Selecting the appropriate dosing strategy requires knowing which index governs the antibiotic-pathogen combination.